Table 2.
Clinical detail of VST recipients
| Patient | Age (years) | Sex | Transplant indication | Type of transplant, HLA mismatch, (cell source other than PBSC) | Conditioning | T‐cell depletion | R/D CMV serostatus | CMV tissue disease | Days of prior antiviral therapy (days) | CMV AUC (log10) prior to first sample for this study | Prior lines of antiviral pharmacotherapy | Degree of HLA match in VSTs | Best virologic response |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 63 | M | AML/MDS | MUD | RIC | ATG | Pos/Neg | Yes | 61 | 6.42 | 2 | 4/6 and 3/6 | PR then death from CMV |
| 2 | 41 | M | T‐NHL | MUD | MAC | Alem | Pos/Neg | No | 27 | 5.06 | 1 | 2/6 and 3/6 | CR |
| 3 | 64 | M | AML | MUD | RIC | ATG | Pos/Neg | No | 23 | 5.83 | 1 | 4/6 and 2/6 | CR |
| 6 | 36 | F | MDS | MSD | RIC | None | Pos/Pos | No | 22 | 5.37 | 2 | 3/6 | CR |
| 7 | 58 | F | ALL | MSD | RIC | ATG | Pos/Neg | No | 44 | 5.74 | 1 | 4/6 | CR |
| 8 | 59 | F | AML | MUD | RIC | ATG | Pos/Neg | No | 31 | 5.69 | 1 | 3/6 | CR |
| 21 | 59 | F | AML | MUD | RIC | ATG | Pos/Neg | No | 50 | NA | 1 | 3/6 and 3/6 | CR |
| 25 | 12 | M | AML | MUD (Cord) | MAC | ATG | Pos/Pos | No | 60 | NA | 1 | 2/6 | CR |
Viral response was defined to be complete response (CR) – complete disappearance of viraemia and partial response (PR) – 50% reduction in viral copy number in the blood.
alem, alemtuzumab; ALL, acute lymphoblastic leukaemia; AML, acute myeloid leukaemia; ATG, anti‐thymocyte globulin; MAC, myeloablative conditioning; MDS, myelodysplastic syndrome; MSD, matched sibling donor; MUD, matched unrelated donor, NA, not available because of the format of reporting of the CMV PCR at the local site; the level is expected to be high given the prolonged use of CMV antiviral therapy prior to study recruitment.